Showing 6451-6460 of 7178 results for "".
- Johnson & Johnson Consumer to Acquire NeoStratahttps://practicaldermatology.com/news/johnson-johnson-consumer-to-to-acquire-neostrata/2458589/Johnson & Johnson Consumer, Inc. has entered into a definitive agreement to acquire NeoStrata Company, Inc. The acquisition will include NeoStrata's affiliates and parent company TriStrata, Incorporated, a privately-held compan
- Galderma Unveils the New Cetaphil Brand Graphics & Packaginghttps://practicaldermatology.com/news/galderma-unveils-the-new-cetaphil-brand-graphics-packaging/2458590/Galderma Laboratories, L.P., redesigned the graphics and packaging of its Cetaphil product line to provide a more simplified shopping experience at shelf, improved portfolio differentiation, as well as clarity of product benefits. "The packaging
- Valeant Names Joseph C. Papa as Chairman and CEOhttps://practicaldermatology.com/news/valeant-names-joseph-c-papa-as-chairman-and-ceo/2458593/Valeant Pharmaceuticals International, Inc's Board of Directors has named Joseph C. Papa to become its Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. He will join Valeant from Perrigo Company plc, a leading global health
- BioPharmX Reports Full Patient Enrollment in Phase 2a Study of BPX-01https://practicaldermatology.com/news/biopharmx-reports-full-patient-enrollment-in-phase-2a-study-of-bpx-01/2458592/BioPharmX Corporation has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01. The Phase 2a study will assess the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo. The endpoints of this study include red
- Checkpoint Inhibitor Shows Promise in MCChttps://practicaldermatology.com/news/checkpoint-inhibitor-shows-promise-in-mcc/2458603/Advanced Merkel cell carcinoma patients who received KEYTRUDA® (pembrolizumab) showed more durable responses than what is typically seen with standard chemotherapy, according to a study presented at the American Association for Cancer Research Annual Meeting 2016 in New Orleans and simul
- New MRF White Paper Provides Road Map for Eradicating Melanomahttps://practicaldermatology.com/news/new-mrf-white-paper-provides-road-map-for-eradicating-melanoma/2458604/More research needs to be done about what range of wavelengths in the ultraviolet band need to be blocked to prevent melanoma, according to a new white paper from Melanoma Research Foundation (MRF). The paper, "The Stat
- Study on TRASER for Nasal Spider Veins Scores Top Honors from ASLMShttps://practicaldermatology.com/news/study-on-traser-for-nasal-spider-veins-scores-top-honors-from-aslms/2458606/Houston dermatologist Paul M. Friedman, MD won the Best of Cutaneous Applications Abstract Session Award for his paper on the use of a novel optical device to treat vexing nasal telangiectasias. The award was presented at the 2016 Annual Conference of the American S
- Recent AAD Meeting Boasts Record Attendancehttps://practicaldermatology.com/news/recent-aad-meeting-boasts-record-attendance/2458607/More than 18,500 people from 107 countries attended the American Academy of Dermatology’s 74th Annual Meeting held in Washington, DC in early March 2016. The meeting featured more than 375 educational sessions, during
- Psoriasis Market Poised for Growth Spurt by 2024https://practicaldermatology.com/news/psoriasis-market-poised-for-growth-spurt-by-2024/2458609/The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a
- Acella Pharmaceuticals Appoints New CEOhttps://practicaldermatology.com/news/acella-pharmaceuticals-appoints-new-ceo/2458613/Acella Pharmaceuticals, LLC, a specialty pharmaceutical company, announced the appointment of Harold. A Deas, Jr. as Chief Executive Officer. Mr. Deas, who will retain his role as Chief Operating Officer, has been instrumental in helping Acella build a successful portfolio of generic and sp